Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
GAITHERSBURG, Md., Nov. 22, 2016 -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference.
Conference details are as follows:
Date: Tuesday, November 29, 2016
Time: 3:30 pm U.S. Eastern Time
Location: New York Palace Hotel, New York, New York
Live webcast: novavax.com, “Investors”/ “Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
